- Unlike other players in its space, biotech royalty aggregator XOMA Corporation (XOMA) focuses on early and mid-stage assets requiring smaller capital commitments.
- Since the company’s pivot to royalty aggregation in 2017, it has accumulated over 70 programs, yet none have reached commercial stage.
- With its first-filed BLA carrying an August 18, 2021 PDUFA date, twelve data readouts over the ensuing year, and little debt, XOMA merited further investigation.
- A full investment analysis and recommendation follows in the paragraphs below.
For further details see:
Xoma Gets The Spotlight